%PDF-1.4
%
29 0 obj
<>
endobj
26 0 obj
<>
endobj
99 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-06T19:44:07Z
2024-03-28T11:15:07-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T11:15:07-07:00
application/pdf
Heather
2003-381.nov
uuid:86c8f199-1dd2-11b2-0a00-370927bd7200
uuid:86c8f19b-1dd2-11b2-0a00-880000000000
endstream
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
30 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.1813 Tw 10 0 0 10 54 712.2551 Tm
[(\(IgA)-376.5 (isotype\) in patients with )54.8 (AS)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 194.9865 715.5551 Tm
(8)Tj
-0.00011 Tc 0.1813 Tw 10 0 0 10 198.2364 712.2551 Tm
[(. )17.7 (Their precise relation)]TJ
0.06329 Tw -14.4236 -1.2 Td
[(with gut inflammation in these patients is still under study)64.8 (.)]TJ
0.02499 Tw 0 -1.2 TD
[(Y)99.8 (et again, this immune feature links )54.8 (AS to IBD.)]TJ
0 Tw 1.2 -1.2 Td
(Lamarque, )Tj
/T1_1 1 Tf
-0.0269 Tw 4.5261 0 Td
(et al)Tj
/T1_0 1 Tf
-0.02679 Tw 1.9458 0 Td
(in this issue of )Tj
/T1_1 1 Tf
[-0.3 (The Journal)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 238.5281 679.5551 Tm
(9)Tj
-0.00011 Tc -0.02679 Tw 10 0 0 10 244.0096 676.2551 Tm
(add an inter-)Tj
0.14011 Tw -19.001 -1.2 Td
(esting piece of evidence to the concept of preclinical and)Tj
0.07671 Tw T*
(premacroscopical immune alterations in the gut of patients)Tj
0.20599 Tw T*
[(with SpA, focussing on a group of patients with )54.9 (AS. In)]TJ
0.13361 Tw T*
[(particular)39.7 (, they describe increased expression of inducible)]TJ
0.2303 Tw T*
(nitric oxide synthase \(iNOS\) as well as increased iNOS)Tj
0.06351 Tw T*
[(activity in the gut mucosa of patients with )54.9 (AS who did not)]TJ
0.0793 Tw T*
(show macroscopical lesions upon endoscopic examination.)Tj
-0.02 Tw T*
[(Moreover)39.7 (, the approach is new in that the authors extend the)]TJ
0.121 Tw T*
[(examination of gut mucosa \(colon\) in patients with )54.9 (AS to)]TJ
-0.02991 Tw T*
[(the upper part of the small intestine \(duodenum\). )54.8 (Also at this)]TJ
0.1124 Tw T*
(site of the gastrointestinal tractus, they identify inflamma-)Tj
0.25169 Tw T*
(tory changes: increased mucosal lymphocytic infiltration)Tj
0.02499 Tw T*
(and increased iNOS expression.)Tj
0.0126 Tc 0.3623 Tw 1.2 -1.2 Td
[(What has become clear from the dif)17.8 (ferent studies)]TJ
-0.00011 Tc 0.0407 Tw -1.2 -1.2 Td
[(describing immune alteration in the gut in patients with )54.8 (AS)]TJ
0.1899 Tw T*
[(and other types of SpA)-385.1 (is that there is a whole immune)]TJ
0.058 Tw T*
(cascade from early preclinical, premacroscopical, and even)Tj
0.3627 Tw T*
(prehistological molecular immune changes to clinically)Tj
0.0199 Tw T*
[(overt Crohn\325)54.8 (s disease. )17.7 (The genetic or environmental factors)]TJ
0.3625 Tw T*
(that determine the progression within this cascade are)Tj
-0.0351 Tw T*
[(lar)17.7 (gely unknown. Indeed, over time, some patients with SpA)]TJ
-0.02901 Tw T*
[(and gut inflammation may reverse to normality)64.8 (, while others)]TJ
0.1915 Tw T*
[(progress to develop overt Crohn\325)54.8 (s disease. )54.8 (A)-386.6 (prospective)]TJ
0.02541 Tw T*
(study from our group was conducted, in which 123 patients)Tj
0.2231 Tw T*
[(with SpA)-418.3 (who previously underwent an ileocolonoscopy)]TJ
-0.02251 Tw T*
(were reviewed clinically after 2 to 9 years)Tj
0 Tc 0 Tw 6.5 0 0 6.5 220.3781 367.5551 Tm
[(10,1)56.7 (1)]TJ
-0.00011 Tc -0.02251 Tw 10 0 0 10 234.6343 364.2551 Tm
[(. )54.8 (At the time of)]TJ
0.1348 Tw -18.0634 -1.2 Td
[(review)64.8 (, 43% of the patients were in clinical remission. In)]TJ
0.0788 Tw T*
[(total, 6.5% of the patients with SpA)-273.9 (who did not present a)]TJ
0.0218 Tw T*
(clinical sign of gut abnormality developed IBD during their)Tj
-0.0067 Tw T*
[(disease course. )54.8 (All these patients initially presented subclin-)]TJ
0.13631 Tw T*
(ical inflammatory gut lesions. In the subgroup of patients)Tj
0.00681 Tw T*
[(with )54.8 (AS, 7.7% developed IBD. Risk factors for evolution to)]TJ
0.25929 Tw T*
(IBD included the presence of chronic inflammatory gut)Tj
0.01109 Tw T*
(lesions, persistence of raised inflammatory serum variables,)Tj
0.2869 Tw T*
(and HLA-B27 negativity in the presence of sacroiliitis.)Tj
0.0199 Tc 0.44769 Tw T*
(Further identification of biomarkers associated with)Tj
-0.00011 Tc 0.19521 Tw T*
[(progression towards overt IBD in patients with SpA)-390.3 (and)]TJ
-0.0197 Tw T*
(early gut mucosal immune changes could open new avenues)Tj
0.049 Tw T*
(for early therapeutic immune intervention in these patients,)Tj
0.02499 Tw T*
[(maybe even during the window of disease reversibility)64.8 (.)]TJ
-0.0246 Tw 1.2 -1.2 Td
[(The recognition of the immune link between )54.9 (AS and SpA)]TJ
0.0472 Tw -1.2 -1.2 Td
(with IBD has given a special impetus towards the develop-)Tj
0.0842 Tw T*
(ment of new therapies in SpA. Indeed, given the immuno-)Tj
-0.03191 Tw T*
[(logical link between the gut in SpA)-163.2 (and IBD on the one hand)]TJ
0.0006 Tw T*
[(and between gut and joint inflammation in SpA)-195.7 (on the other)]TJ
0.0199 Tc 0 Tw T*
(hand)Tj
6.5 0 0 6.5 74.2383 127.5551 Tm
(12)Tj
0.4292 Tw 10 0 0 10 80.9982 124.2551 Tm
(, it was an attractive hypothesis to test that)Tj
0.3813 Tw -2.6998 -1.2 Td
(immunomodulators interfering with gut inflammation)Tj
-0.00011 Tc -0.02969 Tw T*
(would also be of benefit for patients with SpA. Not only was)Tj
0.08749 Tw T*
[(salazopyrine first evaluated and found ef)17.7 (fective in patients)]TJ
0.1198 Tw T*
[(with SpA. More recently)64.8 (, )17.7 (TNF antagonists like infliximab)]TJ
0.15131 Tw 26.4 63.6906 Td
[(have been successfully utilized in )54.8 (AS and SP)91.7 (A)-346.4 (\()0.1 (reviewed)]TJ
-0.0002 Tc 0 Tw T*
(in)Tj
0 Tc 6.5 0 0 6.5 325.7783 704.4616 Tm
(13)Tj
-0.00011 Tc 0.2126 Tw 10 0 0 10 332.2783 701.1616 Tm
[(\). )54.8 (A)-407.7 (special scientific challenge in this respect is the)]TJ
0.06 Tw -1.4278 -1.2 Td
[(finding that more )17.7 (TNF blockers are ef)17.7 (fective in )54.8 (AS than in)]TJ
0.076 Tw T*
(IBD. Etanercept is an example of such a drug with discor-)Tj
0.10361 Tw T*
[(dant ef)17.7 (ficacy in both diseases. )17.7 (The biological basis of this)]TJ
0.02499 Tw T*
(discrepancy is currently being studied.)Tj
/T1_2 1 Tf
10.8 -2.4 Td
[(FILIP)-220.2 (DE KEYSER,)]TJ
/T1_0 1 Tf
6 0 0 6 517.8706 629.1616 Tm
(MD, PhD;)Tj
/T1_2 1 Tf
10 0 0 10 426 617.1616 Tm
(HERMAN MIELANTS,)Tj
/T1_0 1 Tf
0 Tc 6 0 0 6 532.8794 617.1616 Tm
(MD, PhD,)Tj
-0.00011 Tc 8 0 0 8 426 607.1616 Tm
[(Department of Rheumatology)64.8 (, )]TJ
0 -1.25 TD
(Ghent University Hospital, )Tj
T*
(de Pintelaan 185, )Tj
T*
(9000 Ghent, Belgium.)Tj
/T1_1 1 Tf
-13.5 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Mielants.)]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 318 533.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 523.1616 Tm
[(1.)-875.1 (De Keyser F)79.7 (, Elewaut D, De )17.7 (V)128.9 (os M, et al. Bowel inflammation and)]TJ
1.675 -1.25 Td
[(the spondyloarthropathies. Rheum Dis Clin North )54.8 (Am )]TJ
0 Tc 0 Tw T*
(1998;24:785-813.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of)]TJ
1.675 -1.25 Td
(intestinal inflammation related to reactive arthritis. Gut)Tj
0 Tc 0 Tw T*
(1987;28:394-401.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (V)110.8 (an Damme N, Elewaut D, Baeten D, et al. Gut mucosal )17.7 (T)-257.1 (cell)]TJ
1.675 -1.25 Td
(lines from ankylosing spondylitis patients are enriched with alpha E)Tj
T*
(beta 7 integrin. Clin Exp Rheumatol 2001;19:681-7.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Demetter P)110.7 (, De )17.7 (V)128.9 (os M, )17.7 (V)110.8 (an Damme N, et al. Focal upregulation of)]TJ
1.675 -1.25 Td
(E-cadherin-catenin complex in inflamed bowel mucosa but reduced)Tj
T*
[(expression in ulcer)19.7 (-associated lineage. )54.8 (Am J Clin Pathol)]TJ
0 Tc 0 Tw T*
[(2000;1)36.9 (14:364-70.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Demetter P)110.7 (, Baeten D, De Keyser F)79.7 (, et al. Subclinical gut )]TJ
1.675 -1.25 Td
(inflammation in spondyloarthropathy patients is associated with)Tj
T*
[(upregulation of the E-cadherin/catenin complex. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
[(2000;59:21)36.9 (1-6.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Baeten D, Demetter P)110.7 (, Cuvelier C, et al. Macrophages expressing)]TJ
1.675 -1.25 Td
(the scavenger receptor CD163: a link between immune alterations)Tj
T*
[(of the gut and synovial inflammation in spondyloarthropathy)64.8 (. )]TJ
T*
(J Pathol 2002;196:343-50.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Peeters M, Joossens S, )17.7 (V)110.8 (ermeire S, )17.7 (Vlietinck R, Bossuyt X,)]TJ
1.675 -1.25 Td
[(Rutgeerts P)110.7 (. Diagnostic value of anti-Saccharomyces cerevisiae and)]TJ
T*
(antineutrophil cytoplasmic autoantibodies in inflammatory bowel)Tj
T*
[(disease. )54.8 (Am J Gastroenterol 2001;96:730-4.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Hof)17.7 (fman IE, Demetter P)110.7 (, Peeters M, et al. )54.8 (Anti-Saccharomyces)]TJ
1.675 -1.25 Td
[(cerevisiae IgA)-220.2 (antibodies are raised in ankylosing spondylitis and)]TJ
T*
[(undif)17.7 (ferentiated spondyloarthropathy)64.9 (. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2003;62:455-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Lamarque D, )17.7 (T)35 (ran )17.7 (V)110.8 (an Nhieu J, Bernardeau C, et al. L)54.8 (ymphocytic)]TJ
1.675 -1.25 Td
(infiltration and expression of inducible nitric oxide synthase in)Tj
T*
(human duodenal and colonic mucosa is a characteristic feature of)Tj
T*
(ankylosing spondylitis. J Rheumatol 2003;30:2428-36.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (De )17.7 (V)128.9 (os M, Mielants H, Cuvelier C, Elewaut )54.8 (A, )17.7 (V)110.8 (eys E. Long-term)]TJ
2.175 -1.25 Td
[(evolution of gut inflammation in patients with spondyloarthropathy)64.8 (.)]TJ
T*
[(Gastroenterology 1996;1)36.8 (10:1696-703.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Mielants H, )17.7 (V)110.8 (eys EM, Cuvelier C, et al. )17.7 (The evolution of )]TJ
2.1381 -1.25 Td
[(spondyloarthropathies in relation to gut histology)64.8 (. II. Histological)]TJ
T*
(aspects. J Rheumatol 1995;22:2273-8.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Baeten D, De Keyser F)79.7 (, Mielants H, )17.7 (V)110.8 (eys EM. )54.8 (Ankylosing)]TJ
2.175 -1.25 Td
(spondylitis and bowel disease. Best Pract Res Clin Rheumatol)Tj
0 Tc 0 Tw T*
(2002;16:537-49.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (De Keyser F)79.7 (, Baeten D, )17.7 (V)110.8 (an den Bosch F)79.7 (, Kruithof E, Mielants H,)]TJ
2.175 -1.25 Td
[(V)110.8 (eys E. Infliximab in patients with spondyloarthropathy: clinical)]TJ
T*
[(ef)17.7 (ficacy)64.8 (, safety and biological immunomodulation. Rheum Dis Clin)]TJ
0 Tc -0.02991 Tw T*
[(North Am )-54.9 (2003;29:463-79.)]TJ
ET
0 0 0 0 k
420 777 137 -27 re
f*
408 770 150 -25 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
(De Keyser and Meilants: Editorial)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(2307)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
9 0 obj
<>stream
8;Z\7Mitt##iu#8OPdTTP_TSQ`an4Lb-YlGVX*Z%BGLNB\-XT,5kZ4o:bE^1m`6
!KAspa9,4P>R["Y[FR=*nSs.uX)!Y_JM//s\j?b8+`kl/Wr7'BY!`E<#0R
R@ch[lh>PX^TXj!dsM#dg_<=pXMo3(8n'ohEkKsJ9sG$J&>rSVUW!W6a$,diN:%C)
37aKJ]a*ip.>N6&(PcXj+9P/C6(O(KR_t01WiMF$&aGNAHG/.r@,0\.6o7R
^#)1XDtqlGYrX*u;8:aUVI6BDYWCGuO,6.COOc'1bAY\P>4tK-Q,O1YVMU[gJkW''
&0r,7f$Z2o\`dlANeSD,e5`7ulLk36B[klhlZY-6DK0$ZrBSPA2N?FgL`1kUF3kcG
j-^2513JM?b[QkqgO>--1tRcRPNN-UDM](NWW-)U:3n"t3ga",>#MKQ[!tW;`N(UQ
]P,KlZWMlHh$]=&jK<)ZqK:WBLt"g/.9PaFJ/&[U9mODs4ObG2;p(71(C'TY9DU79R64h"lXThSVCf"K'*+hs>U5]+3!=pn5e1:@9\Ul;h2
.FE2o>&s9\TcjMe2?+G\,0;;krl4GQMH=Cdf.4\s)9k63d[M#o%_X^$p!ELo!jY'R
V@I1tP\hVJkMi,PcN(84Cg6~>
endstream
endobj
13 0 obj
[/Indexed/DeviceRGB 255 12 0 R]
endobj
12 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
35 0 obj
<>
endobj
37 0 obj
<>
endobj
4 0 obj
<>
endobj
80 0 obj
<>
endobj
105 0 obj
<>
endobj
5 0 obj
<>
endobj
6 0 obj
<>stream
HL{PW{/lp4cL;35VAq\(BD+ #A#0RT5G]Ԩ|f)u;UnVWswZB$2yIJBbL^ch剧Ѽ'I߇J)?>WELq|RyHv4F 8:0 ]$H$;~:*jVac)Y1sqn0Ɗ16Jg\Qg5z:ِkdMF6P7CNb:]cְiPZkVٜ<>-P)ZĤQ'|14jg.ZoisX:W2FӄDx1ALS$4)1 >!-̊!lC*IC';i%f^&E&9^"8W!
U)[[^WѰkyFJ E''q5'#f=2953CJ('M%5mJ~D;|)T?դcwHAI4x.q(G?X+,8gw*9(7Qb?x241PAl' hnAfDA"PEL`;ʷRunPG6
x]S|Z%[-.~Gh}ɯڻLUJi#yMMyRk}
ly=~^uoJ՛:àm\ -wD8;wJ)}_ϼ d!$we"c8xReKǹ解?2Hɮ>q
*k9y֮+oEW{gJ?aQW \\Z[